Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Project Updates and Milestones news
(page 7)
24 March 2026
WuXi Biologics posts record 2025 results
2025 revenue +16.7% to RMB21.8bn; gross margin +500bps to 46%; EBITDA +38%; net profit +45%; 209 new integrated projects; backlog US$23.7bn; bi-/multi-specifics >120% growth
24 March 2026
Equinor begins Raia pre‑salt gas drilling offshore Brazil
Six wells started 24 Mar with Valaris DS‑17 in ~2,900m water; recoverable >1bn boe; capacity 16m m3/day (~15% national demand); start‑up 2028; $9bn investment; FPSO ~6 kg CO2/boe.
24 March 2026
Vattenfall 2025 Report: Progress Toward Fossil‑Free Energy
Emissions down 56% since 2017 (on 1.5°C path). 2025: SEK30.4bn invested (85% taxonomy), 95 TWh fossil‑free output, wind, nuclear and hydro project approvals; SEK165bn planned 2026–30.
24 March 2026
Teijin Aramid cuts drinking water use by 80% at Chemie Park Delfzijl
Cooling now uses industrial water from salt evaporation, cutting drinking-water use 80% (~300,000 m³), trimming total water use 10% and easing regional supply pressure.
24 March 2026
MAIRE's Nextchem awarded two NX Replast™ feasibility studies for plastic upcycling in Southern Africa and Southeast Asia
Feasibility studies for two mechanical upcycling plants: ~25 KTPA in Southern Africa and 40 KTPA in Southeast Asia to convert polyolefin waste into high-quality compounded r-polymers
24 March 2026
Mitsui Chemicals: Collaborative Rail Freight Enables Same‑Container Continuous Round‑Trips
Demonstration (Aug 2025–Jan 2026) showed multi-shipper collaborative rail freight in Tokai/Chugoku can use same containers for continuous round-trips, cutting CO2 by 57% and guiding logistics plans.
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
24 March 2026
Sinopec Reports 2025 Results in Hong Kong
2025 results: revenue RMB2.78T; profit RMB32.476B; EPS RMB0.268; dividend RMB0.20/share. Oil/gas output rose; refining, chemicals and fuel sales grew; tech/digital advances.
23 March 2026
Roche opens Institute of Human Biology hub to accelerate drug discovery
IHB's new facility opens with space for 250 researchers to develop organoids, organ-on-chip and in silico human models to speed and de-risk drug discovery.
23 March 2026
WACKER expands silicone emulsion production in India
New Panagarh GMP-certified silicone emulsion plant boosts local capacity, adds 60 jobs, serves cosmetics/personal-care customers, lets Amtala shift toward R&D and innovation.
23 March 2026
TotalEnergies ends U.S. offshore wind projects, returns leases to DOI
Signed settlements to relinquish Carolina Long Bay and New York Bight offshore wind leases, recover fees and reinvest equal funds into U.S. gas/LNG and power, citing cost and affordability concerns.
23 March 2026
Veolia to exit coal at Karviná by 2029 with multi‑energy plant
Transforms local heating to RDF/biomass/gas cogeneration (53% RDF), serving ~50,000 households, cutting CO2 by ~200,000 t, improving air quality and energy autonomy.
23 March 2026
BASF converts Ludwigshafen acid chlorides and chloroformates to 100% renewable electricity credits
Average product carbon footprint cut ~19% in 2025; plant modernization raised capacity ~30%; customers get lower‑PCF supplies without recertification, aiding Scope 3 reductions.
23 March 2026
Chugai obtains MHLW approval for Lunsumio–Polivy combo in relapsed/refractory large B‑cell lymphoma
Japan approves Lunsumio + Polivy for relapsed/refractory large B‑cell lymphoma after Phase III SUNMO: ORR 69.7%, PFS 11.5 vs 3.8 months (59% lower progression/death risk); manageable safety.
23 March 2026
Chugai: Roche discontinues GYM329 (emugrobart) development for SMA and FSHD
It showed safety and reduced mature myostatin but failed to deliver consistent functional benefits in SMA/FSHD trials; obesity studies will continue; no expected FY2026 earnings impact.
23 March 2026
Sinopec expands POE capacity with China's first full‑chain domestic IP
100kt solution‑method POE unit began linkage trials; with a 50kt demo and another 100kt under construction, domestic POE capacity reaches 250kt/yr. Metallocene catalyst + low‑VOC devolatilization enable varied grades for PV/EVs.
23 March 2026
Sinopec Among China's Top EV Charging Operators
2025 charging platform exceeded 5 billion kWh (~200% YoY). It is rapidly expanding charging and battery-swap networks with Aodong, NIO and CATL to broaden oil‑gas‑hydrogen‑electric services.
23 March 2026
GSK’s risvutatug rezetecan granted orphan drug designation for SCLC in Japan
Risvutatug rezetecan, a B7-H3–targeted ADC, showed durable responses in extensive‑stage SCLC in phase I ARTEMIS‑001; global phase III in relapsed ES‑SCLC is underway.
20 March 2026
Petrobras contracts two thermoelectric plants in 3rd Capacity Reserve Auction
Contracted two thermoelectric plants in 3rd LRCAP; combined with prior auction totals nine plants (~2.6 GW firm capacity for SIN, 2026–2031). Estimated annual fixed revenue ≈ R$4.45bn.
20 March 2026
TotalEnergies and Holcim open Europe’s largest floating solar plant for self-consumption
31 MW floating solar on a rehabilitated Obourg quarry lake produces 30 GWh/yr for onsite industrial self-consumption; over 700 m of directional drilling links panels to the substation.
20 March 2026
Petrobras resumes investments in Minas Gerais during Lula visit
During Lula’s visit to Regap (Betim), resumption of investments announced: R$3.8bn (2026–30), up to R$9bn/10 yrs; 8k–36k jobs; +25k bpd capacity (2027) and 13.3 MW solar plant.
20 March 2026
FUCHS posts solid FY 2025 results
FY2025: sales €3.56bn, EBIT €435m; EPS +2%; dividend +5% to €1.23/€1.22; free cash flow €316m. 2026 outlook: sales ~€3.7bn, EBIT ~€450m
19 March 2026
FDA approves Novo Nordisk’s Wegovy HD (7.2 mg) after ~21% weight loss in STEP UP trial
Higher‑dose semaglutide injection approved for adults with obesity after tolerating 2.4 mg; 31% reached ≥25% weight loss. Common AEs: GI symptoms and dysesthesia/altered skin sensation. Available April.
19 March 2026
QatarEnergy: Missile strikes cut LNG export capacity 17%, $20bn annual loss
Missile strikes at Ras Laffan damaged LNG Trains 4 & 6; repairs may take 3–5 years with force majeure on contracts. Pearl GTL offline ≥1 year; condensate, LPG, naphtha and helium production affected.
19 March 2026
Aptar’s Unidose Nasal Powder System Used in ENA Respiratory Phase II INNA‑051 Study
Powder nasal device used in a Phase II trial of a once-weekly spray to assess safety, tolerability and reduction of symptomatic infections; device offers single-dose precision and moisture protection.
19 March 2026
OMV and ADNOC delay BGI listing, exchange offer and capital increase to 2027
Timing aligned to a 2027 capital increase; 2026 dividend cut will lower parent payout by ~€0.6–0.7/sh (payout USD250m vs USD500m). Further support measures possible.
19 March 2026
Novo Nordisk: FDA approves Wegovy HD (semaglutide 7.2 mg) — 20.7% mean weight loss
STEP UP: ~31% achieved ≥25% loss; STEP UP T2D mean loss 14.1%. FDA awarded National Priority Voucher. US launch expected April 2026. Safety/tolerability comparable to prior semaglutide doses.
19 March 2026
ADNOC and OMV advance formation of Borouge Group International AG
Agreement allows marketing of B4 volumes, adds ~$400M net over 3 years (~10% EPS accretion), supports 16.2 fils dividend, targets strong credit ratings; transactions close ~Mar 2026.
19 March 2026
Croda opens Dahej manufacturing facility in India
New Dahej plant boosts supply for Life Sciences, Consumer Care and Industrial sectors; uses low‑carbon power, ZLD, RSPO feedstocks, advanced ops, safety focus and women-led packaging.
19 March 2026
GSK: Lynavoy (linerixibat) FDA-approved for cholestatic pruritus in PBC
FDA approved linerixibat for cholestatic pruritus in adults with PBC after GLISTEN phase III showed rapid, sustained itch and sleep improvements. Common AEs: diarrhea, abdominal pain.
19 March 2026
Iberdrola hits 11 GW U.S. generation capacity
Nearly 100 U.S. facilities across 25 states, capacity meets >7M Americans; added 850 MW recently. Plans €16B investment (2025-28) for grids and new generation.
← Previous
Next →
